Patents Assigned to Immurx, Inc.
  • Patent number: 10463731
    Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: November 5, 2019
    Assignee: IMMURX, INC.
    Inventors: Cory Ahonen, Randolph Noelle
  • Patent number: 9238067
    Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: January 19, 2016
    Assignee: IMMURX, INC.
    Inventors: Cory Ahonen, Randolph Noelle
  • Patent number: 8802098
    Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: August 12, 2014
    Assignee: Immurx, Inc.
    Inventors: Cory Ahonen, Randolph Noelle